Abstract
A series of measures to implement national volume-based procurement (NVBP) and follow-on NVBP in China have significantly reduced insulin prices and increased patient affordability. However, NVBP may lead to a higher burden of insulin-related consumables (such as injection pens and needles), which might discourage patients from using insulin in the pooled list and increase the risk of needle reuse. This article emphasizes that it is essential NVBP be implemented for both drugs and consumables, which will contribute to the achievement of universal insulin access.